Accelerating AAV production: optimizing compound identification and process parameters

Wednesday 08:00 PST / 11:00 EST / 16:00 GMT / 17:00 CET

Sponsor

Accelerating AAV production: optimizing compound identification and process parameters

The high cost of gene therapies presents a major challenge, not only in bringing these life-saving treatments to the market but also in making them accessible to patients once available. One of the primary drivers of these costs is insufficient production yields.

In this webinar, Virica Biotech and Culture Biosciences experts will present innovative solutions to address these challenges. Real-world case studies will highlight improved productivity, shorter timelines, and more efficient scale-up. Attendees will gain insights into optimizing AAV production using data-driven solutions, which offer significant advantages over traditional methods.

Virica will showcase how Viral Sensitizers and a Design of Experiments (DoE) workflow can accelerate the identification of compounds that enhance AAV production. Culture Biosciences will demonstrate how a cloud-connected bioreactor platform enables rapid, scalable evaluation of parameters, facilitating the transition from lab-scale to large-scale production.

Identify key challenges that impact AAV production and address these issues using advanced tools and workflows
How to optimize compound identification with high-throughput virology to boost AAV productivity and leverage a cloud-connected bioreactor platform to enable rapid, evaluation of production parameters with transparent data transfer
Explore data comparing the efficiency and yield improvements between DoE-based compound identification and traditional non-DoE methods
See how DoE and cloud bioreactor platforms have been successfully implemented in real-world AAV production, reducing timelines and improving overall process efficiency

Keara Sutherland

Scientist at Virica Biotech

Keara is a devoted and driven MSc graduate in Microbiology and Immunology from the University of Ottawa. She currently works as a Scientist at Virica Biotech, where she integrates her expertise in therapeutics, microbiology, and cancer research to advance viral medicines. Keara has cultivated a profound interest in laboratory automation and Design of Experiments (DOE) methodologies, deriving satisfaction from optimizing automation workflows with a variety of liquid handling systems.

Jean-Marc Guedon

Director, Application Technologies at Culture Biosciences

Jean-Marc is an experienced process development leader within large pharmaceutical and clinical biotechnology companies. He has earned an MSc degree in Molecular Microbiology and Immunology from Johns Hopkins, and a PhD in Molecular Virology and Microbiology from the University of Pittsburgh. Following his postdoctoral work, he held roles of increasing responsibility at Applied Genetic Technologies Corporation and Janssen Research and Development. He has contributed to health authority filings including IND and BLA applications. Currently, he is the Director of Application Technologies at Culture Biosciences lending his expertise to support their pioneering bioprocessing solutions.